For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it

Sponsorship complete. Dine on...

Nutrition, wellness, weight loss, and calmer healthy living.

Synthetic 5-MeO-DMT Shows Promise as a Rapid-Acting Antidepressant

Jul 29, 2026
Synthetic 5-MeO-DMT Shows Promise as a Rapid-Acting Antidepressant

Recent advancements in psychiatric treatment have brought attention to synthetic 5-MeO-DMT, a psychedelic compound originally identified in the secretions of the Sonoran Desert toad. This compound has now entered randomized clinical trials aimed at treating severe depression, marking a significant shift from its previous recreational use. The first randomized, placebo-controlled Phase 2b trial has shown promising results, with participants experiencing substantial reductions in depression severity and remission rates nearing 60 percent after just one treatment day. Importantly, no serious adverse events were reported during the blinded phase of the study, which is a notable achievement in the realm of psychiatric research.

The findings from this trial, led by Cubala and colleagues, represent a crucial milestone in the search for faster-acting antidepressants. Traditional antidepressants often require weeks of daily administration before patients notice improvements. In contrast, inhaled synthetic 5-MeO-DMT produces an intense psychedelic experience that lasts only 15 to 30 minutes, yet early indications suggest that its antidepressant effects could persist for weeks or even months following a single supervised treatment.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it

Sponsorship complete. Dine on...

Eli Lilly's recent announcement of plans to acquire AtaiBeckley for up to $3.8 billion, primarily to access BPL-003, an intranasal formulation of synthetic 5-MeO-DMT, underscores the growing optimism surrounding this compound. This acquisition reflects a broader trend in psychiatry, where psychedelic medicines are transitioning from niche academic research to mainstream pharmaceutical development. Just as the introduction of esketamine established a new category of rapid-acting antidepressants, Lilly's investment may accelerate the development of neuroplasticity-based therapies.

Despite the encouraging results, several critical questions remain unanswered. The inherent challenges of blinding in psychedelic trials complicate the interpretation of results, as participants can often discern whether they received the active compound. Future studies will need to refine their designs to mitigate these expectancy effects. Additionally, the durability of the antidepressant effects remains uncertain. Researchers are keen to understand how long the benefits last after a single treatment and which patients may require repeat dosing.

Safety also continues to be a paramount concern. While the current studies have shown reassuring safety profiles under controlled medical conditions, the risks associated with recreational use of 5-MeO-DMT are significant. Outside of clinical settings, individuals may use unregulated preparations without proper screening or supervision, increasing the likelihood of adverse effects, including psychological distress or psychosis.

As the field progresses, the full safety profile of synthetic 5-MeO-DMT will be established through larger clinical trials and careful post-marketing surveillance if it receives FDA approval. The potential for psychedelic-assisted therapies to provide rapid, lasting changes in mood and cognition presents an exciting frontier in psychiatry. The ongoing research aims to clarify whether these effects stem from enhanced neuroplasticity, profound psychological experiences, or a combination of both.

In summary, synthetic 5-MeO-DMT represents a significant advancement in the treatment of depression, with the potential to transform psychiatric care. The transition from folklore to pharmacology, driven by rigorous clinical trials, marks a pivotal moment in neuropsychopharmacology, with the future of this compound hinging on upcoming Phase 3 trials and regulatory evaluations.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it
Vegetable Prep & Salad Spinners
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it
Kitchen Scales

Kitchen scales for recipes that deserve more precision than 'that looks about right.'

Taste it
Meal Prep Containers

Give tomorrow's lunch a proper home. Containers for meals worth looking forward to.

Taste it
Vegetable Prep & Salad Spinners

Salad spinners and vegetable-prep tools for everyday salads, bowls, and side dishes. A little less kitchen setup, a little more time to enjoy the meal.

Taste it
Blenders & Smoothie Tools

Blenders for fruit, yogurt, soups, and the combinations you actually enjoy. Everyday kitchen tools, not a promise in a glass.

Taste it
Sheet Pans & Roasting Essentials

Sheet pans and roasting racks for vegetables and simple oven meals. Useful equipment for dinner without an elaborate production.

Taste it

Sponsorship complete. Dine on...

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)